@article{JGO120154,
author = {Xijun Luo and Yisi Tu and Danni Wu and Xiuqin Cai and Wenfeng Li and Shibin Yang},
title = {Overexpression of TAZ is associated with downregulation of E-cadherin and indicates poor prognosis in gastric cancer: a clinicopathological study},
journal = {Journal of Gastrointestinal Oncology},
volume = {17},
number = {3},
year = {2026},
keywords = {},
abstract = {Background: Transcriptional co-activator with PDZ-binding motif (TAZ), a key downstream effector of the Hippo signaling pathway, regulates organ size and oncogenesis. However, its clinicopathological significance in gastric cancer (GC) and correlation with E-cadherin remain unclear. Thus, this study aimed to investigate these associations to evaluate TAZ as a prognostic biomarker and therapeutic target.Methods: TAZ messenger RNA (mRNA) and protein levels were assessed in fresh GC tissues and matched adjacent non-tumorous tissues using real-time quantitative polymerase chain reaction (qPCR) (8 pairs) and Western blotting (6 pairs). Additionally, TAZ and E-cadherin expression were evaluated in paraffin-embedded tissues from 98 GC patients and 25 normal controls via immunohistochemistry (IHC).Results: Compared to non-tumorous controls, TAZ mRNA (P=0.03) and protein levels were significantly upregulated in GC tissues. IHC analysis revealed a TAZ positivity rate of 67.3% in GC tissues, markedly higher than the 32.0% observed in normal gastric mucosa (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/120154}
}